Exchange: NYSEArca·Updated 07:30 PM EST

RDIV News

News
all
press releases
More News
Bristol Myers reported that its late-stage ALOFT-IPF trial of the oral drug admilparant met the primary endpoint at the 60 mg twice-daily dose in patients with Idiopathic Pulmonary Fibrosis.
Stocktwits
Target now expects full-year net sales growth in a range around 5%, one percentage point higher than the prior guidance range.
Stocktwits
December jobs data highlight sector shifts as healthcare and restaurants add jobs, while retail lags. ETFs XLV, EATZ in focus.
Zacks
Earnings per share came in at $0.47 compared to a Street expectation of $0.68. Net income dropped nearly 5% year-over-year (YoY) to $1.83 billion. However, revenue came in at $47.81 billion, higher than a Street estimate of $44.88 billion.
Stocktwits

Advertisement|Remove ads.